Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 7/20 | 0.79 |
| ▸ | APAF1 | O14727 | 1/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.71 |
| ▸ | RAD52 | P43351 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | APEX1 | P27695 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378846 | 1.00 | DNM1 (0.79) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL17199719 | 1.00 | DNM1 (0.79) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL4303042 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL4312716 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL4302451 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL4305465 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Cetrimonium SCHEMBL4309906 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Cetrimonium SCHEMBL2556361 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| SCHEMBL6378859 | 0.90 | DNM1 (0.71) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Cetrimonium SCHEMBL11418130 | 0.89 | DNM1 (0.88) | DNM1APAF1HSP90AA1RAD52MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | RELMADA THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-107115326-B | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | 雷尔玛达治疗股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-2557924-B1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | RELMADA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| CN-107115326-A | The dennophannaceutical compositions and its application method of 1 methyl N (2,6 xylyl) 2 piperidine formamides | 雷尔玛达治疗股份有限公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-103491778-B | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | 雷尔玛达治疗股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-103491778-A | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | REIMADA THERAPEUTICS INC | 2014-01-01 | — | — | CN | disclosed |
| EP-2557924-A1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130455-A1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | BABUL NAJIB (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | PIP4K2C, PIP5K1C, PIP4K2A | DNM1 662/4885APAF1 4835/4885HSP90AA1 4069/4885 |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | PIP4K2C, PIP5K1C, PIP4K2A | DNM1 651/4885APAF1 4836/4885HSP90AA1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.